{"id":73065,"date":"2025-07-30T10:56:05","date_gmt":"2025-07-30T08:56:05","guid":{"rendered":"https:\/\/www.cmtc.nl\/pedia\/medicatie\/rly-2608\/"},"modified":"2025-12-07T10:09:57","modified_gmt":"2025-12-07T09:09:57","slug":"rly-2608","status":"publish","type":"page","link":"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/","title":{"rendered":"RLY-2608"},"content":{"rendered":"

At two external conferences (VAC in Berlin<\/a> and ISSVA in Paris<\/a>), we had an exhibition booth. Nearby, there was a booth from the American company Relay. During these conferences, we had extensive contact with Relay staff, and they shared with us information about the development of new medication.<\/p>\n

A Q&A with Brenton Mar from Relay Therapeutics (May 2025)\u202f<\/strong><\/p>\n

\"\"About Brenton Mar: Brenton runs clinical development at Relay Therapeutics, which means he leads the team that creates and runs Relay’s clinical trials.\u202f\u202fBy training, he is a pediatric hematologist\/oncologist and has spent many years doing research and clinical care.<\/p>\n

Who is Relay Therapeutics?<\/strong><\/p>\n

Brenton: Relay Therapeutics is a small biotech company that focuses on discovering and developing new medicines for rare disease and oncology communities with significant unmet needs.<\/p>\n

We were founded in 2016, and you can find most of us in Cambridge, Massachusetts where Relay is based.<\/p>\n

Can you tell us more about your PIK3CA-driven vascular malformations program?<\/strong><\/p>\n

Brenton: One of Relay\u2019s programs is focused on PIK3CA-driven vascular malformations, including PIK3CA Related Overgrowth Spectrum, known as PROS, and PIK3CA-driven lymphatic malformations.<\/p>\n

As you know, PROS includes syndromes such as Klippel-Trenaunay, CLOVES, FAVA, MCAP and many more.<\/p>\n

I\u2019ve mentioned PIK3CA a few times now. PIK3CA is\u202fa gene that creates a protein, called PI3K\u03b1. PI3K\u03b1 is involved in your body\u2019s natural cell growth and metabolism. However, mutations or changes in the PIK3CA gene can lead to a malfunctioning, mutated PI3K\u03b1 protein, which is the most common cause of vascular malformations and other overgrowth syndromes.<\/p>\n

The therapy Relay is investigating in clinical trials, which is called RLY-2608, specifically targets the mutated PI3K\u03b1 protein.<\/p>\n

What is the investigational therapy RLY-2608?<\/strong><\/p>\n

Brenton: The investigational study drug being evaluated is called RLY-2608. It is a drug that is taken orally and is designed to specifically target and hinder the mutated PI3K\u03b1 protein that can cause PIK3CA-driven vascular malformations. By selectively targeting the mutated protein, and limiting impact on the non-mutated proteins, the study drug aims to be an effective treatment that reduces side effects that are caused by hindering the normal protein, including diarrhea, increased blood sugar, rash, mouth sores, and others.<\/p>\n

It\u2019s important to note that RLY-2608 has not yet been evaluated in individuals living with vascular malformations, as Relay is just starting this clinical trial.<\/p>\n

Relay has seen encouraging interim results from our ongoing clinical trial of RLY-2608 in breast cancer, which we shared in December 2024. This breast cancer trial has been running since early 2022.<\/p>\n

Can you tell us more about Relay Therapeutics’ clinical trial for PIK3CA-driven vascular malformations?<\/strong><\/p>\n

Brenton: Earlier this year, Relay started a Phase 2 clinical trial for eligible individuals living with PIK3CA-driven vascular malformations.\u202f The trial will evaluate the safety and effectiveness of the investigational medicine, RLY-2608.<\/p>\n

We\u2019re excited to say that we\u2019ve just opened our first site in the USA in April, and we expect many more sites in the USA to open as the year goes on.\u202f \u00a0The trial is a global trial, and we expect to open sites in additional countries in the future.<\/p>\n

How can people learn more?<\/strong><\/p>\n

Brenton: Please feel free to reach out to Relay Therapeutics with any questions at clinicaltrials@relaytx.com<\/a>. You can learn more about the clinical trial on https:\/\/clinicaltrials.gov\/study\/nct06789913<\/a>.<\/p>\n

Thank you to the patient advocacy groups we have had the opportunity to work with over the past year.\u00a0 We are looking forward to meeting more people in the community throughout the year. Please do not hesitate to reach out.<\/p>\n

Introduction video<\/strong><\/a><\/p>\n

Webinar for people in the USA<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

At two external conferences (VAC in Berlin and ISSVA in Paris), we had an exhibition booth. Nearby, there was a booth from the American company Relay. During these conferences, we had extensive contact with Relay staff, and they shared with us information about the development of new medication. A Q&A with Brenton Mar from Relay […]<\/p>\n","protected":false},"author":2,"featured_media":47675,"parent":69494,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"aw-modules\/awcf_create_page_templates_with_elementor_content\/page-templates\/page-aw-page-template-67351.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-73065","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\nRLY-2608 - CMTC-OVM<\/title>\n<meta name=\"description\" content=\"Nieuwe ontwikkeling: RLY-2608\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RLY-2608 - CMTC-OVM\" \/>\n<meta property=\"og:description\" content=\"Nieuwe ontwikkeling: RLY-2608\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/\" \/>\n<meta property=\"og:site_name\" content=\"CMTC-OVM\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-07T09:09:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2023\/12\/medicine-5238439_1280.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/\",\"url\":\"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/\",\"name\":\"RLY-2608 - CMTC-OVM\",\"isPartOf\":{\"@id\":\"https:\/\/www.cmtc.nl\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2023\/12\/medicine-5238439_1280.jpg\",\"datePublished\":\"2025-07-30T08:56:05+00:00\",\"dateModified\":\"2025-12-07T09:09:57+00:00\",\"description\":\"Nieuwe ontwikkeling: RLY-2608\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/#primaryimage\",\"url\":\"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2023\/12\/medicine-5238439_1280.jpg\",\"contentUrl\":\"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2023\/12\/medicine-5238439_1280.jpg\",\"width\":1280,\"height\":853},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cmtc.nl\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pedia\",\"item\":\"https:\/\/www.cmtc.nl\/en\/pedia\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Treatment\",\"item\":\"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Medication\",\"item\":\"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"RLY-2608\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cmtc.nl\/en\/#website\",\"url\":\"https:\/\/www.cmtc.nl\/en\/\",\"name\":\"CMTC-OVM\",\"description\":\"Global non-profit patient organisation\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cmtc.nl\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RLY-2608 - CMTC-OVM","description":"Nieuwe ontwikkeling: RLY-2608","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/","og_locale":"en_US","og_type":"article","og_title":"RLY-2608 - CMTC-OVM","og_description":"Nieuwe ontwikkeling: RLY-2608","og_url":"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/","og_site_name":"CMTC-OVM","article_modified_time":"2025-12-07T09:09:57+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2023\/12\/medicine-5238439_1280.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/","url":"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/","name":"RLY-2608 - CMTC-OVM","isPartOf":{"@id":"https:\/\/www.cmtc.nl\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/#primaryimage"},"image":{"@id":"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2023\/12\/medicine-5238439_1280.jpg","datePublished":"2025-07-30T08:56:05+00:00","dateModified":"2025-12-07T09:09:57+00:00","description":"Nieuwe ontwikkeling: RLY-2608","breadcrumb":{"@id":"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/#primaryimage","url":"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2023\/12\/medicine-5238439_1280.jpg","contentUrl":"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2023\/12\/medicine-5238439_1280.jpg","width":1280,"height":853},{"@type":"BreadcrumbList","@id":"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/rly-2608\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cmtc.nl\/en\/"},{"@type":"ListItem","position":2,"name":"Pedia","item":"https:\/\/www.cmtc.nl\/en\/pedia\/"},{"@type":"ListItem","position":3,"name":"Treatment","item":"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/"},{"@type":"ListItem","position":4,"name":"Medication","item":"https:\/\/www.cmtc.nl\/en\/pedia\/treatment\/medication\/"},{"@type":"ListItem","position":5,"name":"RLY-2608"}]},{"@type":"WebSite","@id":"https:\/\/www.cmtc.nl\/en\/#website","url":"https:\/\/www.cmtc.nl\/en\/","name":"CMTC-OVM","description":"Global non-profit patient organisation","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cmtc.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/pages\/73065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/comments?post=73065"}],"version-history":[{"count":3,"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/pages\/73065\/revisions"}],"predecessor-version":[{"id":73068,"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/pages\/73065\/revisions\/73068"}],"up":[{"embeddable":true,"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/pages\/69494"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/media\/47675"}],"wp:attachment":[{"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/media?parent=73065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}